San Francisco, June 3rd, 2019 – Recardio Inc., a clinical stage life science company developing regenerative therapies for cardiovascular diseases,announced the first closings of its Series B financing round.
Read MoreRecardio presented at the Cell & Gene Therapy Conference in New York
San Francisco, March 21, 2019 – Recardio announced today that it presented at the Cell & Gene Therapy Conference in New York.
Read MoreRecardio at J.P. Morgan Conference 2019
San Francisco, January 07, 2019 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, today announced that it is participating in the 37thAnnual J.P. Morgan Healthcare Conference on January 7thin San Francisco.
Read MoreRecardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Enrolled First Patients and Recruiting in Multiple Centers
San Francisco, December 13, 2018 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases,announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction has now enrolled the first patients and is now recruiting in multiple European centers. The remaining sites in Europe and in the US will join in the coming months.
Recardio at BIO Investor Forum 2018 in San Francisco
San Francisco, October 17, 2018 – Recardio Inc. presented today its clinical regenerative therapy program for cardiovascular diseases at the international BIO Investor Forum 2018 in San Francisco.